Jounce Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

jouncetx.com

Stage

IPO | IPO

Total Raised

$139M

Date of IPO

1/27/2017

Market Cap

0.24B

Stock Price

4.71

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer through discovering and developing novel cancer immunotherapies with the potential to drive significantly more durable responses to treatment, extending and improving patients' quality of life. Jounce utilizes translational science insights to match the right targets to well defined patient populations in order to achieve a higher probability of success and rapid proof-of-concept. The company is pursuing programs against multiple targets in the T cell checkpoint area, as well as programs beyond T cell checkpoints monotherapies, where current immunotherapies may be less likely to be effective.

Jounce Therapeutics Headquarters Location

1030 Massachusetts Ave

Cambridge, Massachusetts, 02138,

United States

857-259-3840

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Jounce Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Jounce Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Jounce Therapeutics Patents

Jounce Therapeutics has filed 19 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/10/2020

7/12/2022

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Grant

Application Date

4/10/2020

Grant Date

7/12/2022

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Status

Grant

Latest Jounce Therapeutics News

Jounce Therapeutics GAAP EPS of -$0.65 beats by $0.04

Aug 4, 2022

Jounce Therapeutics press release (NASDAQ: JNCE ): Q2 GAAP EPS of -$0.65 beats by $0.04. Cash, cash equivalents and investment of $162.25M Recommended For You Newest To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Jounce Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Jounce Therapeutics Rank

  • Where is Jounce Therapeutics's headquarters?

    Jounce Therapeutics's headquarters is located at 1030 Massachusetts Ave, Cambridge.

  • What is Jounce Therapeutics's latest funding round?

    Jounce Therapeutics's latest funding round is IPO.

  • How much did Jounce Therapeutics raise?

    Jounce Therapeutics raised a total of $139M.

  • Who are the investors of Jounce Therapeutics?

    Investors of Jounce Therapeutics include Celgene, Nextech Invest, Casdin Capital, Pharmstandard International, Omega Funds and 7 more.

  • Who are Jounce Therapeutics's competitors?

    Competitors of Jounce Therapeutics include Tizona Therapeutics.

You May Also Like

ImCheck Therapeutics Logo
ImCheck Therapeutics

ImCheck Therapeutics designs and develops immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: g9d2 T cells and a novel super-family of immunomodulators, butyrophilins. Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck's activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and when used in combination to overcome the resistance to this group of agents. In addition, preclinical experiments with ImCheck’s antagonist antibodies have demonstrated potential as treatments for a wide range of autoimmune diseases. ImCheck Therapeutics was founded in 2015 and is based in Marseille, France.

Tizona Therapeutics Logo
Tizona Therapeutics

Tizona Therapeutics is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system's function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks "self" tissues in the body due to insufficient regulation. Tizona's therapies are designed to regulate these suppressive cells, thereby either activating the body's ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases.

Tesaro Logo
Tesaro

Tesaro is an oncology-focused biopharmaceutical company devoted to providing therapies to people facing cancer. The company seeks to develop and commercialize new treatments.

G
GammaDelta Therapeutics

GammaDelta Therapeutics is an immunotherapy company developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.On October 27th, 2021, GammaDelta Therapeutics was acquired by Takeda Pharmaceutical. The terms of the transaction were not disclosed.

N
NewLink Genetics

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians.

Incyte Logo
Incyte

Incyte seeks to build a product pipeline of small molecule drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.